Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies

NCT02025985 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT02025985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02025985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2014
Completion date
March 29, 2017
Enrollment
116 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical carcinoma, endometrial carcinoma, ovarian carcinoma